Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB
Status:
Recruiting
Trial end date:
2021-08-31
Target enrollment:
Participant gender:
Summary
A single-center, open-label clinical trial to determine the early bactericidal activity (EBA)
and safety of the combination of meropenem and amoxicillin/clavulanate plus pyrazinamide vs.
meropenem and amoxicillin/clavulanate plus bedaquiline administered for 14 consecutive days.
This study forms part of a series of 2-week EBA studies to determine the relative
bactericidal activity of several new or repurposed anti-tuberculosis agents from which to
determine the most effective and safe combination to evaluate in larger and longer duration
regimen-based trials.